Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 43 Results

Title
Intervention Indication Therapeutic Area Year Actions
Alpelisib and Olaparib for treating platinum-resistant or refractory BRCA wild-type ovarian cancer Alpelisib (BYL719; Piqray) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Ovarian cancer Female Reproductive Cancer 2022 View  |  Download
AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Xevinapant (Debio 1143; AT-406) Ovarian cancer Female Reproductive Cancer 2018 View  |  Download
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Atezolizumab with paclitaxel and carboplatin for previously untreated advanced endometrial cancer Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2022 View  |  Download
Avatrombopag for chemotherapy induced thrombocytopenia in patients with nonhaematological cancers Avatrombopag (Doptelet; E5501; avatrombopag maleate) Chemotherapy-induced thrombocytopenia Female Reproductive Cancer , Haematology , Lung and Respiratory Cancer , Toxicology , Urological Cancer 2020 View  |  Download
Avelumab with or without Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer – second line Avelumab (Bavencio; MSB-0010718C) , Pegylated liposomal doxorubicin Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Axalimogene Filolisbac for Cervical Cancer – Beyond First Line Treatment Axalimogene filolisbac (ADXS11-001) Cervical cancer Female Reproductive Cancer 2018 View  |  Download
Bintrafusp alfa for advanced, unresectable cervical cancer Bintrafusp alfa (M7824; GSK4045154) Cervical cancer Female Reproductive Cancer 2021 View  |  Download
Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
1 2 3 4 5
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications